Literature DB >> 15964931

Isogenic human cell lines for drug discovery: regulation of target gene expression by engineered zinc-finger protein transcription factors.

Pei-Qi Liu1, Siyuan Tan, Matthew C Mendel, Richard J Murrills, Bheem M Bhat, Brian Schlag, Rachelle Samuel, Jeanne J Matteo, Ragan de la Rosa, Katherine Howes, Andreas Reik, Casey C Case, Frederick J Bex, Kathleen Young, Philip D Gregory.   

Abstract

Isogenic cell lines differing only in the expression of the protein of interest provide the ideal platform for cell-based screening. However, related natural lines differentially expressing the therapeutic target of choice are rare. Here the authors report a strategy for drug screening employing isogenic human cell lines in which the expression of the target protein is regulated by a gene-specific engineered zinc-finger protein (ZFP) transcription factor (TF). To demonstrate this approach, a ZFP TF activator of the human parathyroid hormone receptor 1 (PTHR1) gene was identified and introduced into HEK293 cells (negative for PTHR1). Following induction of ZFP TF expression, this cell line produced functional PTHR1 protein, resulting in a robust and ligand-specific cyclic adenosine monophosphate (cAMP) response. Reciprocally, the natural expression of PTHR1 observed in SAOS2 cells was dramatically reduced by the introduction of the appropriate PTHR1-specific ZFP TF repressor. Moreover, this ZFP-driven PTHR1 repression selectively eliminated the functional cAMP response invoked by known ligands of PTHR1. These data establish ZFP TF-generated isogenic lines as a general approach for the identification of therapeutic agents specific for the target gene of interest.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964931     DOI: 10.1177/1087057104272663

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  6 in total

1.  Deregulation of focal adhesion formation and cytoskeletal tension due to loss of A-type lamins.

Authors:  Tobias D J Corne; Tom Sieprath; Jonathan Vandenbussche; Danahe Mohammed; Mariska Te Lindert; Kris Gevaert; Sylvain Gabriele; Katarina Wolf; Winnok H De Vos
Journal:  Cell Adh Migr       Date:  2016-11-16       Impact factor: 3.405

2.  A TALE nuclease architecture for efficient genome editing.

Authors:  Jeffrey C Miller; Siyuan Tan; Guijuan Qiao; Kyle A Barlow; Jianbin Wang; Danny F Xia; Xiangdong Meng; David E Paschon; Elo Leung; Sarah J Hinkley; Gladys P Dulay; Kevin L Hua; Irina Ankoudinova; Gregory J Cost; Fyodor D Urnov; H Steve Zhang; Michael C Holmes; Lei Zhang; Philip D Gregory; Edward J Rebar
Journal:  Nat Biotechnol       Date:  2010-12-22       Impact factor: 54.908

Review 3.  Zinc finger nucleases as tools to understand and treat human diseases.

Authors:  David Davis; David Stokoe
Journal:  BMC Med       Date:  2010-07-01       Impact factor: 8.775

4.  Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.

Authors:  Michelle S Bousquet; Jia Jia Ma; Ranjala Ratnayake; Pamela A Havre; Jin Yao; Nam H Dang; Valerie J Paul; Thomas J Carney; Long H Dang; Hendrik Luesch
Journal:  ACS Chem Biol       Date:  2016-03-03       Impact factor: 5.100

5.  A new microsphere-based immunoassay for measuring the activity of transcription factors.

Authors:  Yu-Ling Lin; Yun-Ju Lai; Tai-Chu Peng; Ru-Ping Lee; Kuang-Wen Liao; Nu-Man Tsai; Yen-Ku Liu; Chueh-Jen Tsai
Journal:  Biol Proced Online       Date:  2010-04-14       Impact factor: 3.244

Review 6.  Modern Genome Editing Technologies in Huntington's Disease Research.

Authors:  Tuyana B Malankhanova; Anastasia A Malakhova; Sergey P Medvedev; Suren M Zakian
Journal:  J Huntingtons Dis       Date:  2017
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.